Bayer HealthCare's mission is to provide new treatment options for diseases with high unmet medical need. Bayer HealthCare is committed to innovation and to translating ideas from basic research into novel drugs and also dedicated to fostering collaborations with excellent academic groups and start-ups.
Bayer HealthCare is interested in novel targets and disease-related biomarkers in the fields of:
■Oncology - Focus on anti-proliferative, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, immunotherapy and antibody-drug conjugates.
■Gynecology - Focus on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna) and uterine fibroids (uterine leiomyoma).
■Cardiology - Focus on novel approaches to the care of chronic and/or acute pulmonary hypertension, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and chronic kidney diseases.
■Hematology - Focus on hemophelia, anemia and thrombocytopenia.
The current call for proposals is limited to the above-mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the above-mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets.
There are two different types of grants:
- Support Grants (€5,000-€10,000)
- To further advance research on targets which are at a very early stage of discovery
- Focus Grants (€10,000-€125,000)
- For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug-discovery process.
The size of the individual grant will depend on the target specifics and the phase of validation, but is limited to a maximum of €125,000.
Special conditions may apply for proprietary targets and the in-licensing of targets. Grant types do not need to be selected by the grant applicant. The decision on grant allocation is made at the sole and absolute discretion of Bayer HealthCare.
In addition to the financial support, successful applicants may benefit from the complementary expertise. Bayer HealthCare has a long-standing experience in drug discovery and development as well as a proven track record of collaborations with academic institutes, start-ups, and biotech companies.
Researchers from universities, other academic research institutes and start-up companies from all over the world.
Schedule of Annual Call
The annual submission deadlines are March 31 and August 31.
Bayer HealthCare will inform the results within eight weeks after the respective submission deadline.
A. Online Submission - Deadline: March 31 and August 31 annually.
• All applications can only be submitted via the electronic submission platform.
• The proposal should include a detailed description of the target and highlight its therapeutic potential.
• Please note that only non-confidential information should be provided.
B. Please submit the following documents to NUHS Research Office, NUHS Tower Block, Level 6 - Deadline: 28 Aug 2013 (12 noon), Thursday.
Please visit Bayer HealthCare website for more details.
For NUS and NUH PIs: If the proposed study would requires biospecimen or tissue banking, please contact Dr Eng Chon Boon (email@example.com ) from the NUHS Tissue Repository. The tissue repository will assist in biobanking budgetary. Kindly visit http://medicine.nus.edu.sg/tissue/Cost%20Recovery%20Schedule.pdf
Also visit Ethics and Compliance website for more information.
For NUS PIs:
1. When preparing research budget requests, Indirect Research Costs (IRC) or overhead charges must be provided for in all externally-funded projects. PIs must ensure that the ODRPT's Policy on IRC Administration and Distribution is communicated to potential external grantors/collaborators from the point negotiations start even if it is prior to submission through the University.
2. Goods and Services Tax (GST) is applicable if there are benefits (e.g. IPR and privileged access to research findings) conferred on the grantor in return for the grant. For grants received from foreign organisations ie Bayer Healthcare, GST is chargeable, either at 0% (zero-rated) or 7% (standard rate) depending on the following:
0% - if research work/services rendered by the department are not in connection with land or goods situated in Singapore or;
7% - if research work/services rendered are in connection with land or goods situated in Singapore.
Provision of GST and its arrangement (whether it is inclusive or exclusive of the grant) must be stated in the contract. Please refer to the Guidelines on GST accessible on NUS Staff Portal for more information. For enquiries relating to GST, kindly contact Ms Agnes Lai (firstname.lastname@example.org) or Ms Karen Chew (email@example.com)
Please do not hesitate to contact us if you have any enquires.